vs
Coeur Mining, Inc.（CDE）とIdexx Laboratories（IDXX）の財務データ比較。上の社名をクリックして会社を切り替えられます
Idexx Laboratoriesの直近四半期売上が大きい（$1.1B vs $674.8M、Coeur Mining, Inc.の約1.6倍）。Coeur Mining, Inc.の純利益率が高く（31.9% vs 22.8%、差は9.1%）。Coeur Mining, Inc.の前年同期比売上増加率が高い（120.9% vs 14.3%）。Idexx Laboratoriesの直近四半期フリーキャッシュフローが多い（$326.3M vs $313.3M）。過去8四半期でCoeur Mining, Inc.の売上複合成長率が高い（78.0% vs 6.4%）
Coeur Mining, Inc.はニューヨーク証券取引所に上場する貴金属採掘企業で、北米に5つの鉱山を運営しており、従業員数は2200名です。2012年時点で世界第9位の銀生産量を誇り、2013年にCoeur d'Alene Minesから現在の社名に変更、本社をアイダホ州コーダレンからイリノイ州シカゴに移転しました。
IDEXXラボラトリーズは1983年設立の米国多国籍企業で、伴侶動物獣医療、家畜・家禽、水質検査、乳製品分野向けの製品・サービスの開発・製造・流通を手がけています。本社はメイン州ウェストブルックにあり、EMEA地域の拠点はオランダのホーフドルプに置かれています。
CDE vs IDXX — 直接比較
損益計算書 — Q4 FY2025 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $674.8M | $1.1B |
| 純利益 | $215.0M | $248.2M |
| 粗利率 | — | 60.3% |
| 営業利益率 | 48.6% | 28.9% |
| 純利益率 | 31.9% | 22.8% |
| 売上前年比 | 120.9% | 14.3% |
| 純利益前年比 | 467.9% | 14.8% |
| EPS（希薄化後） | $0.37 | $3.09 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $674.8M | $1.1B | ||
| Q3 25 | $554.6M | $1.1B | ||
| Q2 25 | $480.6M | $1.1B | ||
| Q1 25 | $360.1M | $998.4M | ||
| Q4 24 | $305.4M | $954.3M | ||
| Q3 24 | $313.5M | $975.5M | ||
| Q2 24 | $222.0M | $1.0B | ||
| Q1 24 | $213.1M | $964.1M |
| Q4 25 | $215.0M | $248.2M | ||
| Q3 25 | $266.8M | $274.6M | ||
| Q2 25 | $70.7M | $294.0M | ||
| Q1 25 | $33.4M | $242.7M | ||
| Q4 24 | $37.9M | $216.1M | ||
| Q3 24 | $48.7M | $232.8M | ||
| Q2 24 | $1.4M | $203.3M | ||
| Q1 24 | $-29.1M | $235.6M |
| Q4 25 | — | 60.3% | ||
| Q3 25 | — | 61.8% | ||
| Q2 25 | — | 62.6% | ||
| Q1 25 | — | 62.4% | ||
| Q4 24 | — | 59.8% | ||
| Q3 24 | — | 61.1% | ||
| Q2 24 | — | 61.7% | ||
| Q1 24 | — | 61.5% |
| Q4 25 | 48.6% | 28.9% | ||
| Q3 25 | 31.9% | 32.1% | ||
| Q2 25 | 29.1% | 33.6% | ||
| Q1 25 | 17.3% | 31.7% | ||
| Q4 24 | 21.8% | 27.4% | ||
| Q3 24 | 26.9% | 31.2% | ||
| Q2 24 | 7.5% | 26.3% | ||
| Q1 24 | -1.6% | 31.0% |
| Q4 25 | 31.9% | 22.8% | ||
| Q3 25 | 48.1% | 24.8% | ||
| Q2 25 | 14.7% | 26.5% | ||
| Q1 25 | 9.3% | 24.3% | ||
| Q4 24 | 12.4% | 22.7% | ||
| Q3 24 | 15.5% | 23.9% | ||
| Q2 24 | 0.6% | 20.3% | ||
| Q1 24 | -13.7% | 24.4% |
| Q4 25 | $0.37 | $3.09 | ||
| Q3 25 | $0.41 | $3.40 | ||
| Q2 25 | $0.11 | $3.63 | ||
| Q1 25 | $0.06 | $2.96 | ||
| Q4 24 | $0.11 | $2.62 | ||
| Q3 24 | $0.12 | $2.80 | ||
| Q2 24 | $0.00 | $2.44 | ||
| Q1 24 | $-0.08 | $2.81 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $553.6M | $180.1M |
| 総負債低いほど良い | — | $450.0M |
| 株主資本純資産 | $3.3B | $1.6B |
| 総資産 | $4.7B | $3.4B |
| 負債/資本比率低いほどレバレッジが低い | — | 0.28× |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $553.6M | $180.1M | ||
| Q3 25 | $266.3M | $208.2M | ||
| Q2 25 | $111.6M | $164.6M | ||
| Q1 25 | $77.6M | $164.0M | ||
| Q4 24 | $55.1M | $288.3M | ||
| Q3 24 | $76.9M | $308.6M | ||
| Q2 24 | $74.1M | $401.6M | ||
| Q1 24 | $67.5M | $397.4M |
| Q4 25 | — | $450.0M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $617.8M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $3.3B | $1.6B | ||
| Q3 25 | $3.1B | $1.6B | ||
| Q2 25 | $2.8B | $1.5B | ||
| Q1 25 | $2.7B | $1.4B | ||
| Q4 24 | $1.1B | $1.6B | ||
| Q3 24 | $1.1B | $1.6B | ||
| Q2 24 | $1.0B | $1.6B | ||
| Q1 24 | $1.0B | $1.6B |
| Q4 25 | $4.7B | $3.4B | ||
| Q3 25 | $4.5B | $3.4B | ||
| Q2 25 | $4.2B | $3.3B | ||
| Q1 25 | $4.1B | $3.2B | ||
| Q4 24 | $2.3B | $3.3B | ||
| Q3 24 | $2.2B | $3.4B | ||
| Q2 24 | $2.1B | $3.4B | ||
| Q1 24 | $2.1B | $3.4B |
| Q4 25 | — | 0.28× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.39× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $374.6M | $355.8M |
| フリーキャッシュフロー営業CF - 設備投資 | $313.3M | $326.3M |
| FCFマージンFCF / 売上 | 46.4% | 29.9% |
| 設備投資強度設備投資 / 売上 | 9.1% | 2.7% |
| キャッシュ転換率営業CF / 純利益 | 1.74× | 1.43× |
| 直近12ヶ月FCF直近4四半期 | $665.7M | $1.1B |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $374.6M | $355.8M | ||
| Q3 25 | $237.7M | $402.3M | ||
| Q2 25 | $207.0M | $185.7M | ||
| Q1 25 | $67.6M | $238.0M | ||
| Q4 24 | $63.8M | $262.0M | ||
| Q3 24 | $111.1M | $220.1M | ||
| Q2 24 | $15.2M | $248.3M | ||
| Q1 24 | $-15.9M | $198.6M |
| Q4 25 | $313.3M | $326.3M | ||
| Q3 25 | $188.7M | $371.2M | ||
| Q2 25 | $146.1M | $151.6M | ||
| Q1 25 | $17.6M | $207.9M | ||
| Q4 24 | $16.1M | $232.8M | ||
| Q3 24 | $69.1M | $192.0M | ||
| Q2 24 | $-36.2M | $215.0M | ||
| Q1 24 | $-58.0M | $168.3M |
| Q4 25 | 46.4% | 29.9% | ||
| Q3 25 | 34.0% | 33.6% | ||
| Q2 25 | 30.4% | 13.7% | ||
| Q1 25 | 4.9% | 20.8% | ||
| Q4 24 | 5.3% | 24.4% | ||
| Q3 24 | 22.0% | 19.7% | ||
| Q2 24 | -16.3% | 21.4% | ||
| Q1 24 | -27.2% | 17.5% |
| Q4 25 | 9.1% | 2.7% | ||
| Q3 25 | 8.8% | 2.8% | ||
| Q2 25 | 12.7% | 3.1% | ||
| Q1 25 | 13.9% | 3.0% | ||
| Q4 24 | 15.6% | 3.1% | ||
| Q3 24 | 13.4% | 2.9% | ||
| Q2 24 | 23.2% | 3.3% | ||
| Q1 24 | 19.8% | 3.1% |
| Q4 25 | 1.74× | 1.43× | ||
| Q3 25 | 0.89× | 1.47× | ||
| Q2 25 | 2.93× | 0.63× | ||
| Q1 25 | 2.03× | 0.98× | ||
| Q4 24 | 1.69× | 1.21× | ||
| Q3 24 | 2.28× | 0.95× | ||
| Q2 24 | 10.69× | 1.22× | ||
| Q1 24 | — | 0.84× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
CDE
セグメントデータなし
IDXX
| Vet Lab Consumables | $389.0M | 36% |
| Reference Laboratory Diagnostic And Consulting Services | $349.2M | 32% |
| Rapid Assay Products | $76.0M | 7% |
| Recurring Revenue | $70.6M | 6% |
| CAG Diagnostic Capital Instruments | $58.1M | 5% |
| Water Segment | $50.5M | 5% |
| Livestock And Poultry Diagnostics Segment | $37.5M | 3% |
| CAG Diagnostics Service And Accessories | $35.3M | 3% |
| Systems And Hardware | $20.1M | 2% |
| Rebate And Up Front Considerations Arrangements | $2.4M | 0% |
| Extended Warranties And Post Contract Support Revenue | $1.0M | 0% |
